North America Bioreactors Market size was valued at USD 256.1 million in 2018 and is expected to witness 17.6% CAGR from 2019 to 2025.
Get more details on this report - Request Free Sample PDF
The North America bioreactors market is driven by growing biopharmaceuticals and biologics industry. The growth of biopharmaceutical industry can be attributed to rising prevalence of chronic diseases, growing aging population and increased investment in technological advances; especially in the personalized and targeted therapies. The bioreactors industry is largely driven by technological advancements related to bioreactor material, design and processing. Various technological innovation such as continuous manufacturing, process analytical technology, and single-use systems in bioreactors contribute to advancements in biological processes. Hence, the above-mentioned reasons will augment bioreactors market growth over the forecast timeframe.
Growing demand for personalized medicines is another chief growth augmenting factor. The number of personalized medicines targeting a specific population of patients has increased in the recent years. Personalized medicine has an increasing need for portable, rapid, scalable, and flexible bio-manufacturing system that can be monitored online for consistent, affordable, and safe production of biologics thus, accelerating the demand for bioreactors.
North America Bioreactors Market, By Cell
Mammalian cell segment held maximum revenue shares accounting for USD 200.4 million revenue size in 2018.Wide array of application such as production of therapeutic proteins and viral vaccines will augment the segmental growth. Stirred-tank bioreactors are most widely used for mammalian cell culture processes.Hence, growing demand for mammalian cells owing to higher efficiency and productivity compared to prokaryotic cells will augment segmental growth.
Bacterial cell segment is witnessing lucrative growth of 17.2% during the forecast period. High growth rate is attributed to various benefits associated with bacterial cells. Advantages such as ease of culture, low by-product concentration, high tolerance to osmolality, and higher expression levels are high growth rendering factor. Moreover, low cost of maintaining bacterial cell culture will be conducive to segmental growth.
North America Bioreactors Market, By Molecule
Monoclonal antibodies generated over USD 102.7 million in 2018. The term monoclonal antibody suggests that man-made antibody is synthesized from cloned immune cells, to produce an identical monoclonal antibody that binds to one type of antigen. Monoclonal antibody segment is expected to hold large chunk of revenue during the analysis period owing to its increasing application in treatment of asthma, breast cancers, rheumatoid arthritis, psoriasis, leukemia, chronic gastrointestinal inflammatory disease, and transplant rejection.
Vaccines segment will grow at about 17.3% with expectations to surpass USD 190 million by 2025. Vaccines are one of the most effective medication for treatment of infectious diseases. Increasing applications of vaccines in the treatment of various infectious diseases coupled with increasing prevalence of various communicable diseases will augment segmental growth.
North America Bioreactors Market, By Technology
Wave-induced motion SUB segment accounted for revenue size of USD 130.0 million in 2018 and is expected to witness substantial growth across the forecast timeframe. High growth is attributed to its extensive use in modern biotechnological processes. Furthermore, increasing focus of manufacturers for development of technological advanced bioreactors will propel market growth.
Stirred SUBs technology segment is expected to witness favourable growth of 17.6% over the projected timeframe owing to its huge demand in the biopharmaceutical industry. The ability to reduce scale-up risks and maintain clean environment throughout the production process should stimulate industry growth.
North America Bioreactors Market, By End-use
Biopharma manufacturers held about 33% of industry share in 2018. Biopharma manufacturers are estimated to experience lucrative growth across the analysis period due to increase in the number of biopharmaceutical products in pipeline including antibodies and antibody drug conjugates coupled with rising number of new facilities to meet the production needs.
R&D organizations held the largest revenue of 127.9 million in 2018 and is projected to witness strong growth over the forecast years. High growth is due to increasing number of biopharmaceutical companies and biosimilar producers entering into strategic collaborations with new entrants to facilitate business expansion.
North America Bioreactors Market, By Country
U.S. bioreactors market recorded revenue size of USD 238.0 million in 2018. Factors such as presence of major players operating in the U.S. bioreactors market along with rising venture capital investment in development of advance technology-based bioreactors in the recent years will augment bioreactors market growth in the country. U.S. is in forefront for technology adoption and the country is working towards developing smart manufacturing infrastructure that will help operators to make real time use of bioreactors, thereby boosting the market growth.
Some of the major industry players involved in North America bioreactors market include Thermo Fisher Scientific, GE Healthcare, Merck Group, Sartorius Stedim Biotech Group, GEA Group Aktiengesellschaft, etc. The North America bioreactors market is highly fragmented with many small and medium players stretched across U.S. and Canada. Companies mainly focus on new product launch, geographical expansion, acquisition strategy, agreements, and collaborations to stay ahead in the competition.
North America Bioreactors Industry Background
During the initial phase, bioreactor was used as a single-use bag developed with the purpose of storage and transport. GE launched its first wave-induced bioreactor in 1996 that marked the beginning of specialized single-use bioreactors. Early 2000 witnessed limited number of products and various issues in scaling of the products but with time technological advancements were given priority. Technological developments showed the increased adoption rate of bioreactors over the U.S. The adoption rate of the bioreactors is highest in the U.S. due to cGMP (current good manufacturing practice) being followed in the country. Similarly, major players such as Sartorius and GE healthcare are focusing on increasing investment in R&D for the development of new technologies that focus on improving microbial culture, mixing and temperature control.